Ahmet Çakır

Ahmet Çakır

Auto-generated profile, based on publicly available information

Ahmet Çakır

Inonu University

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 December 2023 in Turkish Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
AÇAhmet Çakır
Ahmet Çakır
HMHasan Memiş
Hasan Memiş
ZGZeynep Ülkü Gün
Zeynep Ülkü Gün
MBMurat Bıçakcıoğlu
Murat Bıçakcıoğlu
The study aimed to identify drug-related problems (DRPs) and risk factors associated with the emergence of DRPs in intensive care unit (ICU) patients. This retrospective study included patients in the anesthesiology and reanimation ICU of a university-affiliated tertiary care hospital. DRPs identified by clinical pharmacists were classified using the Pharmaceutical Care Network Europe Classification for DRPs version 9.1. The association between various patient-related factors, and having DRPs were evaluated. In total, 222 patients were included in the study, 128 of which were male (57.7%). The number of DRPs was 388 in 135 patients (1.75 ± 2.47 DRPs per patient). The group in which at least 1 DRP was identified, the duration of hospitalization was longer than in the group in which no DRP was identified (p < 0.001). In the groups in which there was the presence of mechanical ventilation support at admission or mortality, the mean DRP count was significantly higher than that in the other group (p < 0.05). Age, duration of hospitalization, and the Acute Physiology and Chronic Health Evaluation (APACHE) II score at admission had positive relationships with the DRP count, but the Glasgow Coma Scale (GCS) showed a negative relationship (p < 0.05). According to the binary logistic regression analysis (p < 0.001), in which the age of the patient, GCS score, APACHE II score at admission, duration of hospitalization, and presence of mechanical ventilation support at admission were included, only the APACHE II score at admission and duration of hospitalization significantly affected the emergence of DRPs. The major problem was related to treatment effectiveness (47.9%), followed by treatment safety problems (29.9%). The major causes of these problems were dose selection (44.0%) and drug selection (36.8). Interventions were made at the drug (97.2%) and prescriber level (2.3%). The acceptance rate of interventions and resolution rate of the DRPs were 93.6% and 85.1%, respectively. The top three medications that caused DRPs the most were as follows: meropenem, colistin, and piperacillin/tazobactam. Clinical pharmacists can detect and treat DRPs quickly. Our analysis shows that clinical pharmacy services are needed in high-DRP wards like ICU.

26 June 2025 in Infectious Diseases and Clinical Microbiology
Verified
Journal Article
Open access
HMHasan Memis
Hasan Memis
ACAhmet Cakir
Ahmet Cakir
ZGZeynep Ulku Gun
Zeynep Ulku Gun
HSHatice Saracoglu
Hatice Saracoglu
CKCigdem Karakukcu
Cigdem Karakukcu
ZDZafer Dogan
Zafer Dogan
Healthcare-associated infections are frequently encountered in intensive care units (ICUs), with more than 30% of all ICU admissions having an infection. For decades, antibiotics have provided an effective treatment for infectious diseases. Since most antibiotic resistance is caused by misuse or abuse of antibiotics, one of the strategies that could

23 February 2026 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
SKSena Güzel Karahan
Sena Güzel Karahan
MDMefküre Durmuş
Mefküre Durmuş
AÇAhmet Çakır
Ahmet Çakır
ZGZeynep Ülkü Gün
Zeynep Ülkü Gün
SYSezai Yılmaz
Sezai Yılmaz
Background: Medication-related problems (MRPs) are a common patient safety issue among hospitalized individuals, often associated with reduced quality of life, increased healthcare costs, and higher mortality. Due to the chronic and complex nature of post-transplant care, liver transplant recipients are particularly vulnerable to MRPs. Clinical pharmacists play a critical role in identifying and resolving MRPs, thereby promoting the rational use of medications. The objective of this study was to characterize MRPs among liver transplant recipients and assess the clinical determinants associated with their occurrence. Method: This prospective study was conducted between 5 October 2023 to 31 April 2024 at the Liver Transplantation Institute. A total of 373 hospitalized liver transplant recipients in inpatient wards and intensive care units who were receiving at least one medication were included. Donors and patients not receiving any medication were excluded. The Pharmaceutical Care Network Europe (PCNE) classification system version 9.1 was used to categorize MRPs. Clinical and demographic characteristics of patients with and without MRPs were compared statistically and risk factors were analyzed through logistic regression. Results: Among the 373 patients included in this study, at least one MRP was identified in 311 patients, yielding 620 MRPs in total. A total of 620 interventions were proposed, of which 547 (88.2%) were accepted, while 73 (11.8%) were rejected. The leading causes of MRPs was “dose selection” (C3) was the most common cause (44.2%), followed by “drug selection” (C1) at 26.1%. The presence of at least one comorbidity and acute kidney injury were significant risk factors for the occurrence of MRPs (p < 0.05). Conclusion: To our knowledge, this is the first and most comprehensive study applying the PCNE v.9.1 method to liver transplant recipients hospitalized in both ward and intensive care unit settings. The most prevalent MRPs were related to “treatment effectiveness,” primarily caused by “dose selection” and “drug selection.” Clinical pharmacists and physicians should particularly focus on these aspects when reviewing transplant patients’ medication regimens. The results achieved in this study suggest that clinicians should exercise caution when prescribing new medications to transplant recipients with at least one comorbidity and a history of acute kidney injury.

10 January 2024 in European Journal of Hospital Pharmacy
Verified
Journal Article
Closed access
PDF file
HMHasan Memiş
Hasan Memiş
AÇAhmet Çakır
Ahmet Çakır
AÜAyşe Ülgey
Ayşe Ülgey
Augmented renal clearance (ARC) is a condition in which renal circulation increases, causing drug levels in the blood to remain at subtherapeutic levels in severe trauma patients. Vancomycin, a hydrophilic anti-Gram-positive drug, has been shown in the literature to have its levels fall below the therapeutic range in the case of ARC. However, vancomycin dosing recommendations in the case of ARC are still lacking. Here, we identify an ARC case measured with urinary creatinine clearance in a severe trauma paediatric patient, causing vancomycin blood trough levels to drop. We could not be able to increase the vancomycin trough levels with intermittent dosing; hence, we administered vancomycin with continuous infusion, and this resulted in vancomycin blood trough levels remaining in the therapeutic range. No adverse effect was seen. Continuous infusion of vancomycin can be safely administered to paediatric patients in these cases.

26 June 2025 in Infectious Diseases and Clinical Microbiology
Verified
Journal Article
Open access
HMHasan Memis
Hasan Memis
ACAhmet Cakır
Ahmet Cakır
APAysel Pehlivanli
Aysel Pehlivanli
BBBILGEN BASGUT
BILGEN BASGUT
Antibiotic resistance has become a significant public health concern, primarily due to irrational antibiotic use. Healthcare and antimicrobial stewardship depend on using antibiotics correctly for several reasons. In the first place, adhering to the prescribed dosage ensures that the body receives the right amount of antibiotics to treat

20 March 2023 in Ankara Universitesi Eczacilik Fakultesi Dergisi
Verified
Journal Article
Closed access
HMHasan Memi̇ş
Hasan Memi̇ş
AÇAhmet Çakir
Ahmet Çakir
NÖNesligül Özdemi̇r
Nesligül Özdemi̇r
ZGZeynep Ülkü Gün
Zeynep Ülkü Gün
Objective: This study seeks to identify potential drug-drug interactions (pDDIs) in hospitalized patients and compare two commercial drug interaction databases. Material and Method: This prospective cross-sectional study was conducted between February and May 2022 in a tertiary care hospital's general pediatric ward. UpToDate® and Micromedex® Drug Interaction databases were used to determine pDDIs. Result and Discussion: In total, 267 pDDIs were found in 51 pediatric patients' medication lists (181 via UpToDate® and 86 via Micromedex®). The use of at least five different systemic drugs concurrently was statistically significant between groups of patients who experienced at least one pDDI and those who did not. The binary logistic regression analysis showed that a one-drug increase in the total number of drugs a patient received during hospitalization increased the probability of pDDIs by 2.12-fold (CI: 1.321-3.417, p=0.002). The concordance rate between UpToDate® and Micromedex® databases for pDDI determination was 84.31% (kappa coefficient=0.676, standard error=0.102, (p ≤ 0.001)). When the UpToDate® database was assumed as a reference database, the Micromedex® database's sensitivity, specificity, positive predictive value, negative predictive value, and accuracy in determining pDDIs were 79.41%, 94.12%, 96.43%, 69.56%, and 84.5%. To avoid missing pDDIs, utilizing multiple drug interaction databases may be of benefit.